Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.

OBJECTIVE Tumor invasion involves degradation of extracellular matrix. The urokinase plasminogen activation system participates in this process. Urokinase-type plasminogen activator (uPA), its receptor (uPAR), and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), are proposed to be prognostic factors in some cancers. There are conflicting data regarding the prognostic role of this system in endometrial cancer. METHODS To determine the prognostic value of the urokinase plasminogen activation system, contents of uPA, uPAR, and PAI-1 were measured in extracts of endometrial cancer tissue using ELISAs. uPA, uPAR, and PAI-1 levels were determined in 91, 54, and 92 extracts, respectively, and correlated with tumor histology, stage, grade, lymph node involvement, prevalence of metastasis, and recurrence as well as with estrogen (ER), progesterone (PR), epidermal growth factor (EGFR) receptor and HER-2/neu contents. RESULTS Patients with cancers exhibiting advanced stage, high grade, unfavorable tumor histology, nodal involvement, recurrence, and lower PR levels determined by ligand binding had significantly higher uPA content than others. PAI-1 was significantly elevated in patients with advanced stage, high-grade tumor, recurrence, decreased ER content, and lower PR levels determined by ligand binding. uPAR did not show any relation to any of clinical and laboratory parameters. Elevated expression of PAI-1 was associated with significantly shorter disease-free (P = 0.005) and overall (P = 0.0003) survival. Multivariate analysis revealed that PAI-1 was a predictor of survival although stage was the strongest independent factor. CONCLUSION Elevated uPA and PAI-1 levels appear to correlate with unfavorable prognosis in endometrial cancer.

[1]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[2]  F. Jänicke,et al.  Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. , 1997, Gynecologic oncology.

[3]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[4]  M. Fernö,et al.  Urokinase‐plasminogen‐activator levels and prognosis in 69 soft‐tissue sarcomas , 1996, International journal of cancer.

[5]  K. Ulm,et al.  Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma , 1996, Cancer.

[6]  D. Doering,et al.  Quantitative analyses of epidermal growth factor receptors, HER‐2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri , 1996, Cancer.

[7]  H. Allgayer,et al.  Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.

[8]  H. Sasano,et al.  Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. , 1995, Human pathology.

[9]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[10]  H. Kobayashi,et al.  Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. , 1994, Cancer research.

[11]  P. Dettmar,et al.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.

[12]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[13]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[14]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[15]  K. Becker,et al.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. , 1994, Cancer research.

[16]  R. Bast,et al.  Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer , 1994, Cancer.

[17]  H. Nekarda,et al.  Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer , 1994, The Lancet.

[18]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[19]  J. Bonnar,et al.  Plasminogen activator inhibitors in endometrial adenocarcinoma , 1993 .

[20]  W. Creasman.  Prognostic significance of hormone receptors in endometrial cancer , 1993, Cancer.

[21]  J. Mikuta.  International federation of gynecology and obstetrics staging of endometrial cancer 1988 , 1993, Cancer.

[22]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[23]  J. Bonnar,et al.  Uterine fibrinolytic enzymes in endometrial cancer. , 1993, European journal of gynaecological oncology.

[24]  S. Cha,et al.  HER-2/neu expression: A major prognostic factor in endometrial cancer , 1992 .

[25]  J. Bonnar,et al.  The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. , 1992, Gynecologic oncology.

[26]  A. Sumiyoshi,et al.  The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.

[27]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[28]  K. Danø,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[29]  K. Sugimachi,et al.  Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. , 1991, Cancer research.

[30]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[31]  P. Schwartz,et al.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. , 1990, American journal of clinical pathology.

[32]  L. Orci,et al.  Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.

[33]  Y. Takada,et al.  The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. , 1990, Thrombosis research.

[34]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[35]  B. Djulbegovic,et al.  Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding , 1990, Journal of clinical laboratory analysis.

[36]  A. Schally,et al.  Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer , 1989, Journal of clinical laboratory analysis.

[37]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[38]  K. Danø,et al.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. , 1986, The Journal of biological chemistry.

[39]  G. Markus.  The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of Cancer , 1984, Seminars in thrombosis and hemostasis.

[40]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  A. NovoGonzalez,et al.  [Adenocarcinoma of the uterus]. , 1960, Clinica y laboratorio.